The Artificial Intelligence in Oncology Market, estimated at USD 2,145.1 Mn in 2025, is expected to exhibit a CAGR of 33.7% and reach USD 16,382.0 Mn by 2032.
Market expansion is fueled by growing adoption of digital healthcare solutions, rising demand for efficient data management, and continuous advancements in health IT infrastructure. Increasing integration of electronic health records (EHRs), telehealth platforms, and AI-driven analytics is enhancing patient care, operational efficiency, and decision-making. Strategic collaborations, evolving business models, and supportive regulatory frameworks are creating strong growth prospects for both emerging players and established healthcare IT providers.
Increasing organic growth strategies, such as product launches by key market players, are expected to drive market growth over the forecast period. For instance, on October 27, 2023, Koninklijke Philips N.V., a Netherlands-based multinational health technology company, announced that it had launched a new AI-based imaging and reporting tool for early detection of prostate cancer.
Global Artificial Intelligence in Oncology Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2019 as "coronavirus disease 2019" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others, faced problems with regard to the transportation of drugs from one place to another.
The coronavirus (COVID-19) pandemic and resulting lockdown in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare sector is one of the sectors that has been majorly impacted by the COVID-19 pandemic. It has also affected the growth of the pharmaceutical businesses of various companies globally due to lockdowns implemented by the governments of several countries. The nationwide lockdowns have led to the closure of industrial establishments, except for the manufacturing of essential commodities, and disruptions in the supply chain of the pharmaceuticals. For instance, during the COVID-19 pandemic, there was a reduction in non-emergency surgical procedure, which impacted the growth of the market. According to an article published by journal of JAMA Network Open, an open access journal, in December 2021, titled 'Trends in US Surgical Procedures and Health Care System Response to Policies Curtailing Elective Surgical Operations During the COVID-19 Pandemic', the pandemic had affected every aspect of medical care, including the surgical treatments. The article analyzed the surgical data in the U.S. from November 2020 through July 2021 and indicated that the initial shutdown period in March 2020 through April 2020 was associated with a decrease in surgical procedure volumes. After the restrictions were lifted, the rate of surgical procedures rebounded to 2019 levels.